Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Zevra Therapeutics (ZVRA) Long-Term Debt Issuances (2022 - 2024)

Zevra Therapeutics' Long-Term Debt Issuances history spans 4 years, with the latest figure at $59.0 million for Q2 2024.

  • For Q2 2024, Long-Term Debt Issuances rose 51845.61% year-over-year to $59.0 million; the TTM value through Sep 2025 reached $59.0 million, down 5.8%, while the annual FY2024 figure was $59.0 million, 39.03% up from the prior year.
  • Long-Term Debt Issuances reached $59.0 million in Q2 2024 per ZVRA's latest filing, up from $3.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $59.0 million in Q2 2024 to a low of -$114000.0 in Q2 2023.
  • Average Long-Term Debt Issuances over 3 years is $19.0 million, with a median of $12.9 million recorded in 2022.
  • Peak YoY movement for Long-Term Debt Issuances: crashed 100.89% in 2023, then soared 51845.61% in 2024.
  • A 3-year view of Long-Term Debt Issuances shows it stood at $12.8 million in 2022, then tumbled by 71.64% to $3.6 million in 2023, then surged by 1525.07% to $59.0 million in 2024.
  • Per Business Quant, the three most recent readings for ZVRA's Long-Term Debt Issuances are $59.0 million (Q2 2024), $3.6 million (Q4 2023), and $26.0 million (Q3 2023).